-

Tempus to Report Second Quarter 2025 Financial Results on August 8

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the second quarter of 2025 on Friday, August 8, 2025. The company will hold the earnings conference call at 8:00 a.m. ET. The company’s quarterly earnings will be released the same day.

The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus’ Investor Relations website. Alternatively, the call can be accessed via the following:

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Contacts

Tempus Communications
Erin Carron
Erin.carron@tempus.com

Tempus Investor Relations
Elizabeth Krutoholow
investorrelations@tempus.com

Tempus AI, Inc.

NASDAQ:TEM

Release Versions

Contacts

Tempus Communications
Erin Carron
Erin.carron@tempus.com

Tempus Investor Relations
Elizabeth Krutoholow
investorrelations@tempus.com

More News From Tempus AI, Inc.

Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that it has been selected by the Advanced Research Projects Agency for Health (ARPA-H), an agency within the U.S. Department of Health and Human Services, to receive an award of up to $9.5 million to build the first autonomous clinical AI agent capable of providing safe and effective care to patients suffering from heart failure. Funding provided through ARPA-H’s ADVOCATE (Agentic AI-EnableD CardioVascular CAre TransfOrmati...

Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced that Founder and CEO Eric Lefkofsky will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026, at 8:30 a.m. ET in New York City.A live audio webcast of the conversation will be available here.About TempusTempus AI is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of t...

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM) today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Tempus ECG-PH (pulmonary hypertension), an AI-enabled software device that analyzes standard 12-lead electrocardiograms (ECGs) for signs associated with pulmonary hypertension. Tempus ECG-PH is the third FDA-cleared device in Tempus’ growing cardiovascular portfolio, expanding the company’s suite of next-generation AI products aimed at ide...
Back to Newsroom